What is HC Wainwright's Forecast for ORKA Q1 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Oruka Therapeutics in a report issued on Monday, April 28th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.62) for the quarter. HC Wainwright currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.74) EPS and FY2026 earnings at ($2.75) EPS.

Other analysts have also recently issued reports about the stock. Wedbush reissued an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 7th. Wolfe Research began coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $39.86.

Oruka Therapeutics Stock Down 5.5 %

NASDAQ:ORKA traded down $0.59 during mid-day trading on Wednesday, reaching $10.13. 67,936 shares of the company were exchanged, compared to its average volume of 233,443. The stock has a market cap of $379.09 million, a PE ratio of -1.62 and a beta of 0.25. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $31.13. The company has a fifty day moving average of $9.99 and a 200 day moving average of $16.07.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.19.

Insider Activity at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the acquisition, the insider now directly owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. The trade was a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders bought 98,339 shares of company stock worth $1,128,456. 22.67% of the stock is currently owned by company insiders.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics in the 4th quarter valued at approximately $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter worth $119,000. China Universal Asset Management Co. Ltd. bought a new position in Oruka Therapeutics in the fourth quarter valued at $144,000. Cannon Global Investment Management LLC acquired a new stake in Oruka Therapeutics in the 1st quarter valued at $195,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Oruka Therapeutics during the 4th quarter worth about $236,000. Institutional investors and hedge funds own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.